[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606586":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":44,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":30,"whyStopped":18,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-MY6349 PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: 68Ga-MY6349 PET\u002FCT",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DIAGNOSTIC_TEST",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Deling Li, MD","STUDY_CHAIR",[24],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","+86 13810098236","lideling@bjtth.org",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Beijing","Beijing Municipality","100070","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Deling Li","Professor",[49],{"name":50,"class":6},"Peking Union Medical College Hospital","100606586","immunopet-targeting-trophoblast-cell-surface-antigen-2-trop-2-in-craniopharyngioma-patients-100606586",false,"NCT07177482","ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients","Inclusion criteria:\n\n* must be able to provide a written informed consent\n* radiologically presumed and\u002For histologically confirmed craniopharyngioma scheduled for resection\n* adequate clinical condition (Karnofsky performance status ≥70)\n\nExclusion criteria:\n\n* concomitant major central nervous system disorders\n* severe hepatic or renal dysfunction\n* history of severe allergy or hypersensitivity to intravenous radiographic contrast agents\n* claustrophobia precluding PET\u002FCT or MRI examinations\n* pregnancy or breastfeeding","ALL","14 Years","80 Years",{"count":61,"type":62},20,"ESTIMATED","INTERVENTIONAL",[65],"NA","This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.",[68],"Craniopharyngioma",[70,71],"Positron-Emission Tomography","Diagnosis","2025-09-10",{"date":74,"type":75},"2025-09-17","ACTUAL",{"date":77,"type":75},"2025-07-04",{"date":79,"type":62},"2026-12-31",{"name":46,"class":6},1]